Presented by Dr Leigh Goedeke, Yale School of Medicine this webinar details using spontaneous NHP models of NAFLD and metabolic syndrome to assess a controlled-release mitochondrial protonophore (CRMP). Explore proof-of-concept data from these clinically relevant models, supporting the development of novel liver-targeted mitochondrial uncouplers to treat human NASH and T2D.

The tumor homograft MuScreen^TM is now available in a smaller panel, covering 6 different indications and with each model harboring clinically-relevant mutations. Screen your I/O agent efficacy in these fully immunocompetent models that have never been passaged in vitro.

Explore the benefits of imaging orthotopic, metastatic models. Read our new White Paper to learn more about key model utilities for studying disease progression and metastasis, and for assessing novel agents for different disease stages.

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

To celebrate the Grand Opening of our new San Diego site we're offering a free arm on subcutaneous syngeneic model studies. You can choose from any validated syngeneic model offered at our US location for studies with at least 5 arms and n=10/arm.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

Presented by Dr Guodong Zhang this webinar focuses on new solutions to overcome preclinical NAFLD/NASH research challenges. Explore the pros and cons of a range of preclinical NASH models, as well as alternative liver disease evaluation methods, to help optimize and progress your drug development programs.

We presented posters on our unique translational NASH model at the ADA Scientific Sessions this year. Download our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.

Explore advanced models and novel I/O technologies for pancreatic cancer research. Learn more about orthotopic tumor homografts, more accurately replicating PDAC TME in vivo for more clinically-relevant preclinical studies. Discover CAR-T cell therapy as a potential new treatment strategy for pancreatic cancer.

Learn how to optimize syngeneic translatability through proof of concept and target engagement studies. Read our new White Paper to explore how panels of syngeneic models are used to evaluate new single agent and combination regimens, uncover biomarkers of I/O response, and discover common PD markers for predicting population response.

Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform.

Advance your NASH therapeutics with the inherently dysmetabolic, obese, and diabetic MS-NASH mouse (formerly FATZO). Learn more about standard NASH induction on Western diet plus fructose, as well as accelerated disease progression and exacerbated pathology with CCl₄ administration. Explore new CCl₄ data, including improved lipid profile and NAS score with OCA treatment.

Presented by Dr Andrew Puca this webinar focuses on novel techniques for optimizing preclinical diabetes research with spontaneously diabetic NHPs. Learn more about continuous glucose monitoring and the banana tolerance test, and how reducing invasiveness and stress leads to improved study data and clinical outcomes.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.